pulmonary arterial hypertension
Cardiovascular · 2005–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sotatercept Add-on therapy for the treatment of adult patients with Group 1 pulmonary arterial hypertension (PAH) WHO Functional Class II or III who have been on stable… | Mar 2025 | Not recommended | 227 individuals Lung Foundation Australia · Australian Scleroderma Interest Group |
| tadalafil Treatment of pulmonary arterial hypertension (PAH), specifically for use in combination with endothelin receptor antagonists. | Mar 2024 | Recommended | input received Lung Foundation Australia |
| macitentan with tadalafil Continuing treatment of pulmonary arterial hypertension (PAH) in patients who are on stable doses of macitentan and tadalafil as combination therapy. | Nov 2024 | Recommended with restriction | input received Lung Foundation Australia |
| selexipag Triple therapy for patients with WHO Functional Class III or IV pulmonary arterial hypertension (PAH) on inadequate response to dual therapy with an endothelin… | Jul 2020 | Recommended with restriction | 113 individuals Pulmonary Hypertension Network Australia · Lung Foundation Australia · PAH Association of Australia |
| selexipag Treatment of pulmonary arterial hypertension (PAH) in patients with WHO functional class II, III or IV symptoms, including idiopathic, heritable, connective… | Mar 2017 | Not recommended | 33 individuals |
| selexipag Treatment of pulmonary arterial hypertension (PAH) in patients with inadequate response to stabilised endothelin receptor antagonist (ERA) or phosphodiesterase… | Mar 2016 | Recommended with restriction | 3 individuals |
| epoprostenol Long-term treatment via continuous intravenous infusion in WHO functional Class III or Class IV patients with idiopathic pulmonary arterial hypertension,… | Nov 2016 | Recommended with restriction | none received |
| bosentan; epoprostenol; macitentan Pulmonary arterial hypertension (PAH) — continuing treatment in patients who have completed initial 48 weeks of treatment. | Jul 2015 | Recommended with restriction | 9 individuals Pulmonary Hypertension Australia |
| epoprostenol Long-term treatment via continuous intravenous infusion in WHO functional class III or IV patients with idiopathic pulmonary arterial hypertension, familial… | Jul 2014 | Recommended | no section in document |
| macitentan Idiopathic pulmonary arterial hypertension (IPAH), PAH secondary to connective tissue disease (PAH-CTD), and PAH associated with congenital heart disease… | Mar 2014 | Recommended with restriction | unclear |
| riociguat Treatment of primary pulmonary hypertension, pulmonary arterial hypertension (PAH) secondary to connective tissue disease, and PAH associated with congenital… | Mar 2014 | Recommended with restriction | unclear |
| epoprostenol sodium Treatment of WHO functional class III pulmonary arterial hypertension (PAH) secondary to scleroderma spectrum of diseases in patients who have failed prior… | Nov 2011 | Recommended with restriction | no section in document |
| tadalafil Treatment of WHO functional class III primary pulmonary arterial hypertension (PAH) and WHO functional class III PAH secondary to connective tissue disease. | Nov 2011 | Recommended with restriction | no section in document |
| tadalafil Treatment of WHO functional class III primary pulmonary arterial hypertension (PAH) and WHO functional class III PAH secondary to connective tissue disease. | Nov 2011 | Recommended with restriction | no section in document |
| ambrisentan Treatment of primary pulmonary hypertension (PPH) or pulmonary arterial hypertension secondary to connective tissue disease (PAH-CTD) in patients with WHO… | Jul 2009 | Recommended with restriction | no section in document |
| bosentan monohydrate Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts including Eisenmenger's physiology (APAH-CHD) in patients with WHO… | Mar 2008 | Recommended with restriction | no section in document |
| treprostinil sodium Treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of… | Nov 2005 | Recommended | no section in document |
| treprostinil sodium Treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of… | Nov 2005 | Recommended | no section in document |
Who spoke
Lung Foundation Australia · Pulmonary Hypertension Australia · Pulmonary Hypertension Network Australia · PAH Association of Australia · Australian Scleroderma Interest Group
What the PBS pays
$216M in government benefit over 2024–25, across 142,870 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| macitentan with tadalafil | $78.4M |
| macitentan | $66M |
| selexipag | $26.7M |
| tadalafil | $12.6M |
| riociguat | $11.5M |
| ambrisentan | $8.5M |
| epoprostenol | $6M |
| epoprostenol sodium | $6M |
| bosentan monohydrate | $0.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| sotaterceptSotatercept for treating pulmonary arterial hypertension | TA1161 | recommended | 2026-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.